KZR

Kezar Life Sciences, Inc. [KZR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

KZR Stock Summary

Top 10 Correlated Stocks

KZR

In the News

KZR Financial details

Company Rating
-
Market Cap
62.81M
Income
-99.91M
Revenue
7M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
58
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.79
Forward P/E
-
PEG
-0.19
P/S
9.45
P/B
0.31
P/C
-
P/FCF
-0.82
Quick Ratio
13.51
Current Ratio
13.83
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.38
EPS next Y
-
EPS next Q
-
EPS this Y
44.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
37.5%
-
-
-
-
SMA20
-3.97%
SMA50
-15.62%
SMA100
-89.21%
Inst Own
-
Inst Trans
-
ROA
-34%
ROE
-35%
ROC
-0.42%
Gross Margin
100%
Oper. Margin
-1384%
Profit Margin
-1200%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.67-3.13
52W High
-
52W Low
-
RSI
42.98
Rel Volume
0.01
Avg Volume
750.67K
Volume
7.73K
Perf Week
-0.82%
Perf Month
-11.68%
Perf Quarter
-90.15%
Perf Half Y
-90.41%
-
-
-
-
Beta
0.481
-
-
Volatility
0.2%, 0.19%
Prev Close
-5.47%
Price
6.05
Change
-5.02%

Something similar

Top by Market Cap
LLY.DE
ABEC.DE
3V64.DE
V
BRYN.DE
Same Sector
CMRX
600566.SS
KRYS
XBRANE.ST
RNAZ
Top Correlated Stocks
RGEN
MCVT
HUM
TFX
0L73.L
Similar Market Cap
DGP
GGRO.TO
DYFN
MHN.L
WM.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 750.67K
  • Market Capitalization 62.81M
  • Employee 58
  • CEO Dr. Christopher J. Kirk Ph.D.
  • Headquarters South San Francisco,CA,US
  • IPO Date 2018-06-21
  • Website https://www.kezarlifesciences.com

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.